The treatment of breast cancer gets better every year, more precise, more effective. But to Hoag, better is not good enough.
Hoag’s Cancer Clinical Research Program works to improve the tools physicians can use to treat diseases of all types, including offering several innovative trials targeting advanced breast cancer.
Hoag has many breast cancer clinical trials available to the community, many of which focus on innovation and clinical advancement. Some of these include:
Molecular Imaging of Estrogen Receptors (ER) – Hoag is using ER-targeted imaging to sensitively detect disease extent in patients with ER-positive breast cancers, both at initial diagnosis and when there is suspicion for disease recurrence.
By finding advanced disease that is being missed on other types of breast imaging, Hoag can assist patients in avoiding surgeries and other procedures that would not have been effective.
I-SPY – Hoag is the first hospital in Orange County to open the innovative, practice-changing I-SPY trial, a national trial that tests several novel drugs for the treatment of early breast cancer.
Quilt NK Cancer Breast Trial – Hoag is initiating a novel natural killer, or “NK” cell, trial using cellbased combination immunotherapy for advanced breast cancer. This trial looks to harness the power of immunotherapy in the treatment of breast cancer.
Hoag’s involvement in clinical trials means Orange County patients don’t have to wait to get the latest and most effective treatments possible.
“Hoag has a very serious commitment to our patients,” said Deborah Fridman, PsyD, R.N., Executive Director, Hoag Clinical Research. “We’re very focused on participating in clinical trials that have the potential to be effective treatment options now and in the future.”
For information on our current trials, please contact clinicalresearch@hoag.org.
October is Breast Cancer Awareness Month
Hoag encourages women to maintain their breast health by being “breast aware,” getting a yearly physical and obtaining screening mammograms (recommended annually for women ages 40 and older). This is key in the early detection of cancer, when treatment can be most effective.
